DiscoveRx Corporation Adds 7 New Kinase Assay Toolboxes to HitHunter Portfolio
Flourescence Polarization Line to Broaden the Range of DiscoveRx Assay Kits for Kinase Targets
Fremont, Calif. DiscoveRx Corporation announced the availability of a new range of kinase assay toolboxes to its expanding line of assays for high throughput screening. The ready-to-use toolboxes cover a broad range of kinase targets. These toolboxes combine all the components required for customers to develop high throughput screening assays for kinases based on fluorescence polarization, but give the customers the flexibility to optimize the buffer conditions and assay parameters as required by their target. Components include proprietary antibodies, tracers, substrates and standards. Currently available assays include PKC19-31, Syntide, Crosstide, GS-derived peptide, ATF, AMARA and MBP. Additional toolboxes fir a very broad range of kinases will be available soon. "The availability of these toolboxes will simplify and shorten the assay development time required to setup high throughput screening assays for new kinase targets," said Pyare Khanna, President, CEO, and Founder of DiscoveRx Corporation. "Customers will have the flexibility to optimize the assay for their needs; in addition, they will have the necessary components and parameters ready for screening." The HitHunter product line features homogeneous assays for the most popular targets in drug discovery, such as G- protein coupled receptors (GPCRs), kinases, and nuclear hormone receptors. The assays are homogeneous, which greatly simplifies and speeds optimization for automation, as well as provides customers the flexibility to use a number of existing detection instruments already in their labs.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous